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he Eye as an
ndicator of Heart
ailure in Diabetic Patients*
ector O. Ventura, MD, FACC,
adhavi Reddy, MD
ew Orleans, Louisiana
n 1855, Eduard Jaeger, an Austrian physician, was the first
o painstakingly portray the retinal findings associated with
iabetes in his seminal work “Beitrage zur Pathologie des
uges” (1). With a newly developed direct ophthalmoscope,
e produced one of the first atlases containing 21 color
lates of fundus paintings and described a “roundish” or oval
ellowish spots and full or partial thickness extravasations
hrough the retina in the macular region of a diabetic
atient (1). Jaeger findings of the association between
iabetes and retinal changes were controversial and were not
dopted by the medical community. The debate as to whether
acular changes were directly related to diabetes or whether
hey were caused by atherosclerosis and hypertension was
nresolved at the beginning of the 20th century, until Arthur
ames Ballantyne, suggested that diabetic retinopathy repre-
ents a unique form of vasculopathy and his work showed for
he first time the role of capillary wall alterations in the
evelopment of diabetic retinopathy as well as the presence of
eep waxy exudates in the outer plexiform layer (2).
See page 1573
More than 150 years after the original description,
esearchers have correlated diabetic retinopathy with a
isease that Jaeger and others probably did not encounter
oo often: heart failure (HF).
Heart failure is today a common cause of morbidity and
ortality worldwide. In the U.S. alone, HF occurs in more
han 5 million people and it accounts for more than 1
illion hospital stays. In addition, $33 billion in health care
osts annually are spent on patients with HF (3).
Research on the etiology of HF has focused on diseases
hat have traditionally been thought to reflect macrovascular
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.d
From the Department of Cardiology, Cardiomyopathy and Heart Transplantation,
chsner Clinic Foundation, New Orleans, Louisiana.amage, such as hypertension (HTN), myocardial infarc-
ion, diabetes, and renal dysfunction (4,5). There has not been
uch focus on microvascular disease as a harbinger of HF.
Although several studies have linked microvascular dam-
ge and the development of coronary heart disease (CHD)
6–14), Wong et al. (15) were the first to show with a large
opulation-based database that retinopathy is an indepen-
ent predictor of congestive HF. With the ARIC (Athero-
clerosis Risk in Communities) study (a prospective cohort
tudy of atherosclerosis risk factors in 4 U.S. communities),
hey studied the relationship between retinopathy and
ew-onset HF. In 11,612 healthy middle-aged participants,
hey found an almost 2-fold-higher risk of HF for those
atients with retinopathy after controlling for common
HD risk factors such as age and blood pressure. Most
nterestingly, further analysis revealed that in diabetic pa-
ients without history of CHD or HTN, the presence of
etinopathy conferred a 4-fold increase in risk of HF (risk
atio of 4.32 with 95% confidence interval 2.13 to 9.76). In
ddition the population-attributable fraction of retinopathy
n the diabetic patient without CHD or HTN was an
stounding 30.5%, implying that microvascular disease
ight play a significant role in the pathophysiology of HF
n diabetes. However, this subgroup analysis was restricted
y a significant number of unaccounted confounders (e.g.,
enal dysfunction and glycemic control) (15).
In this issue of the Journal, Cheung et al. (16) elegantly
xpand on their prior work to describe the relationship
etween diabetic retinopathy and the development of HF
hile controlling for several of the confounders in their
riginal study. Again with the ARIC database, they fol-
owed 1,021 diabetic patients with normal renal function
nd no evidence of coronary disease or HF for 9 years. The
uthors found that, in this group of otherwise healthy
iabetic patients, those with baseline retinopathy were more
han twice as likely to develop HF as patients without
etinopathy at baseline. This increased risk persisted after
ontrolling for common HF risk factors including age,
ender, smoking history, blood pressure, lipid profile, and
ther risk factors such as race, diabetes duration, and insulin
se (hazard rate 2.71). Further adjustments for glycemic
ontrol, carotid atherosclerosis, and markers of endothelial
ysfunction did not change the results significantly (hazard
ate 2.20). Almost 1 in 4 (this changes to 1 in 5) diabetic
atients with baseline retinopathy developed HF (cumula-
ive incidence of 21.6%), whereas only 1 in 10 (1 in 12)
atients without baseline retinopathy developed HF (cumu-
ative incidence of 8.5%). Even mild retinopathy (defined as
inimal, nonproliferative retinopathy) conferred an in-
reased risk with a hazard rate of 1.91, whereas moderate-
evere retinopathy (defined as moderate-severe nonprolif-
rative retinopathy or proliferative retinopathy) conferred a
igher risk with a hazard rate of 2.38 (16).
There are some limitations to the conclusions we can
raw from this study. As the authors note, some of the
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Editorial Comment April 22, 2008:1579–80iochemical markers (e.g., glycosylated hemoglobin) were
btained, on average, 3 years before the bulk of the data.
nother weakness is the fact that only white and black
mericans were included in this study, limiting its applicability
o other races. Lastly, a considerable number of the diabetic
atients had sub-par retinal photographs and were thereby
xcluded, introducing the possibility of selection bias. Most
mportantly, this study shows an association between diabetic
etinopathy and HF but certainly does not prove causality.
The mechanism by which microvascular disease as man-
fested by retinopathy might play a role in the pathophysi-
logy of HF in diabetes remains to be elucidated. Retinop-
thy has been associated with inflammatory markers and
easures of endothelial dysfunction such as C-reactive protein
nd serum soluble intercellular adhesion molecule-1 (17,18). It
s possible that retinopathy is an early sign of inflammation and
ndothelial dysfunction that eventually leads to coronary mi-
rovascular disease and HF. Another explanation is that
etinopathy simply lies along a continuum of disease that
ventually leads to macrovascular damage and HF. Clarifying
he relative contribution of micro- and macrovascular damage
o HF in diabetic patients is vital from etiological, preventive,
nd therapeutic perspectives.
In summary, this is the first large prospective population-
ased study finding that in the diabetic patient the presence
f retinopathy confers an increased risk for developing HF
ven in the absence of conventional risk factors. For the
hysician, this finding might have important clinical impli-
ations in the care of diabetic patients. The current guide-
ines already identify the need for routine screening for
etinopathy in the diabetic patient. In addition to appropri-
te vision care, the detection of retinopathy might now also
arrant a fuller cardiac evaluation and closer follow-up to
revent the development of HF.
Sixteen hundred years ago Saint Jerome said “. . . eyes
ithout speaking confess the secrets of the heart” (19).
ever was this truer than when examining the relationship
etween retinopathy and HF in diabetes.
eprint requests and correspondence: Dr. Hector O. Ventura,
chsner Clinic Foundation, 1514 Jefferson Highway, New Or-eans, Louisiana 70121. E-mail: HVentura@ochsner.org.EFERENCES
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